Pharma Focus Asia

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

Friday, January 18, 2019

Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, today announced the expansion of its existing non-exclusive perpetual license agreement with Eli Lilly and Company. The expanded rights will more broadly enable EIi Lilly to use the AlivaMab Mouse platform for projects with collaborators, including the right to grant sub-licenses to antibody drug candidates much earlier in discovery. Financial terms of the agreement include an undisclosed upfront payment from Eli Lilly. Any potential milestones and royalties on product sales would be paid by the sub-licensees of the AlivaMab Mouse platform.

“This agreement further advances Ablexis’ goal of making AlivaMab Mouse more broadly available for the discovery of the next generation of antibody-based therapeutics,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis and AlivaMab Discovery Services, LLC. “Within the span of just a few weeks the AlivaMab Mouse platform consistently delivers diverse panels of high-affinity, high-potency antibodies with favorable developability qualities and reduced chance of immunogenicity. This represents a significant advantage over in vitro display approaches or other transgenic animal platforms. We look forward to continue making AlivaMab Mouse the platform of choice for experienced antibody drug discoverers and developers.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024